We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The U.S. Food and Drug Administration (FDA) approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive.....
Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome, the two most common subtypes of cutaneous T-cell lymphoma, a rare type of non-Hodgkin’s lymphoma.